Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PTAFR | P25105 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2704044 | 0.74 | POLB (0.62) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL4563285 | 0.71 | KDM4E (0.63) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL9819800 | 0.70 | PTAFR (0.69) | KDM4EALDH1A1ALOX15PTAFRSIGMAR1 | |
| SCHEMBL7892245 | 0.70 | KDM4E (0.59) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL4799264 | 0.70 | ALDH1A1 (0.62) | KDM4EALDH1A1GAAPOLBMAPT | |
| SCHEMBL4169559 | 0.70 | SIGMAR1 (0.67) | KDM4EALDH1A1ALOX15SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4799421 | 0.69 | KDM4E (0.58) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL9819753 | 0.69 | PTAFR (1.00) | KDM4EALDH1A1ALOX15PTAFR | |
| SCHEMBL15103054 | 0.69 | KDM4E (0.55) | KDM4EALDH1A1ALOX15PTAFRPOLB | |
| Bromide SCHEMBL4174825 | 0.69 | SIGMAR1 (0.65) | KDM4EALDH1A1ALOX15SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414048-B2 | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| EP-1119568-B1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-18 | — | — | EP | disclosed |
| US-20040019059-A1 | 4,5-Dihydro-isoxazole derivatives and their pharmaceutical use | FREYNE EDDY JEAN EDGARD (BE) | 2004-01-29 | — | — | US | disclosed |
| US-6583141-B1 | T cell mediated rheumatic diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-24 | — | — | US | disclosed |
| EP-1119568-A1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021959-A1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019059-A1 | 4,5-Dihydro-isoxazole derivatives and their pharmaceutical use | CBR1, CYP2D6, HSD3B1 | KDM4E 2853/4885ALDH1A1 396/4885ALOX15 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.